Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response
- 23 January 2001
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 1 (2) , 307-319
- https://doi.org/10.1016/s1567-5769(00)00028-x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator?Immunology Today, 1998
- REGULATION OF IMMUNE RESPONSES BY TGF-βAnnual Review of Immunology, 1998
- Escape from Host-Antitumor ImmunityCritical Reviews™ in Oncogenesis, 1997
- The role of cytokines in cancerCytokine & Growth Factor Reviews, 1996
- Lymphokine Production by Human T Cells in Disease StatesAnnual Review of Immunology, 1994
- Biological properties of interleukin 10Immunology Today, 1992
- Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.The Journal of Experimental Medicine, 1991
- Some recent advances in the chemistry and biology of transforming growth factor-beta.The Journal of cell biology, 1987
- Cancer chemotherapeutics as immunomodulatorsSpringer Seminars in Immunopathology, 1985